Market Place
Sourcing Support
Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024
09 Sep 2024 //
BUSINESSWIRE
Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022
05 Sep 2022 //
BUSINESSWIRE
AstraZeneca`s novel checkpoint inhibitor flunks first phase 3
02 Aug 2022 //
FIERCEBIOTECH
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
01 Aug 2022 //
BUSINESSWIRE
Patient Dosed in Monalizumab Phase 3 Lung Cancer Trial Triggers $50M Payment
29 Apr 2022 //
BUSINESSWIRE
Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity
09 Dec 2021 //
BUSINESSWIRE
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
02 Dec 2021 //
BUSINESSWIRE
Innate Pharma Third Quarter 2021 Report
16 Nov 2021 //
BUSINESSWIRE
Here`s Why Innate Pharma Stock Is Rocketing Higher Today
17 Sep 2021 //
FOOL
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
17 Sep 2021 //
BIOSPACE
INNATE PHARMA TO PRESENT ADDITIONAL EFFICACY DATA FOR MONALIZUMAB
04 Dec 2020 //
PRESS RELEASE
Innate to Present New Efficacy Data For Monalizumab in Combination Cetuximab
14 May 2020 //
GLOBENEWSWIRE
Innate Pharma announces Phase III clinical trial of monalizumab
28 Sep 2019 //
CLINICALTRIALSARENA
Innate Pharma and AstraZeneca take monalizumab into phase 3
27 Sep 2019 //
PMLIVE
AstraZeneca digs deeper into cancer with Innate stake
23 Oct 2018 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.